Emerging Strategies to Overcome Resistance to Third-generation EGFR Inhibitors

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2022 Jul 15

PMID 35840984

Authors

Kunyu Shi

Guan Wang

Junping Pei

Jifa Zhang

Jiaxing Wang

Liang Ouyang

Yuxi Wang

Weimin Li

Affiliations

Soon will be listed here.

Abstract

Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related to the inhibition of tumor cell proliferation, angiogenesis, invasion, metastasis, and apoptosis. Therefore, EGFR has become an important target for the treatment of cancer, including non-small cell lung cancer, head and neck cancer, breast cancer, glioma, cervical cancer, and bladder cancer. First- to third-generation EGFR inhibitors have shown considerable efficacy and have significantly improved disease prognosis. However, most patients develop drug resistance after treatment. The challenge of overcoming intrinsic and acquired resistance in primary and recurrent cancer mediated by EGFR mutations is thus driving the search for alternative strategies in the design of new therapeutic agents. In view of resistance to third-generation inhibitors, understanding the intricate mechanisms of resistance will offer insight for the development of more advanced targeted therapies. In this review, we discuss the molecular mechanisms of resistance to third-generation EGFR inhibitors and review recent strategies for overcoming resistance, new challenges, and future development directions.

Citing Articles

Targeting Non-Eosinophilic Immunological Pathways in COPD and AECOPD: Current Insights and Therapeutic Strategies.

Razia D, Gao C, Wang C, An Y, Wang F, Liu L Int J Chron Obstruct Pulmon Dis. 2025; 20:511-532.

PMID: 40066199 PMC: 11892741. DOI: 10.2147/COPD.S506616.

An innovative approach to development of new pyrazolylquinolin-2-one hybrids as dual EGFR and BRAF inhibitors.

Hawwas M, Mancy A, Ramadan M, Ibrahim T, Bayoumi A, Alswah M Mol Divers. 2025; .

PMID: 40056327 DOI: 10.1007/s11030-025-11127-4.

Dickkopf-1 promotes tumor progression of gefitinib- resistant non-small cell lung cancer through cancer cell-fibroblast interactions.

Choi M, Choi Y, Lee Y, Lee Y, Chung J, Kang K Exp Hematol Oncol. 2025; 14(1):24.

PMID: 40025612 PMC: 11871833. DOI: 10.1186/s40164-025-00616-9.

Metformin inhibits the growth of SCLC cells by inducing autophagy and apoptosis via the suppression of EGFR and AKT signalling.

Xia H, Tai X, Cheng W, Wu Y, He D, Wang L Sci Rep. 2025; 15(1):6081.

PMID: 39971923 PMC: 11839993. DOI: 10.1038/s41598-025-87537-z.

Research on detection methods of related substances and degradation products of the antitumor drug selpercatinib.

Xiang J, Cai L, Wang Q, Zhu Y, Han Y Front Chem. 2025; 12:1534132.

PMID: 39872362 PMC: 11770003. DOI: 10.3389/fchem.2024.1534132.

References

Chamberlain P, Hamann L . Development of targeted protein degradation therapeutics. Nat Chem Biol. 2019; 15(10):937-944. DOI: 10.1038/s41589-019-0362-y. View

Lei H, Fan S, Zhang H, Liu Y, Hei Y, Zhang J . Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors. Eur J Med Chem. 2019; 186:111888. DOI: 10.1016/j.ejmech.2019.111888. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Jang J, Son J, To C, Bahcall M, Kim S, Kang S . Discovery of a potent dual ALK and EGFR T790M inhibitor. Eur J Med Chem. 2017; 136:497-510. PMC: 5800871. DOI: 10.1016/j.ejmech.2017.04.079. View

Qiu Y, Yin X, Li X, Wang Y, Fu Q, Huang R . Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication. Pharmaceutics. 2021; 13(5). PMC: 8158526. DOI: 10.3390/pharmaceutics13050747. View

Westover D, Zugazagoitia J, Cho B, Lovly C, Paz-Ares L . Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018; 29(suppl_1):i10-i19. PMC: 6454547. DOI: 10.1093/annonc/mdx703. View

Mueller K, Madden J, Zoratti G, Kuperwasser C, List K, Boerner J . Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res. 2012; 14(4):R104. PMC: 3680928. DOI: 10.1186/bcr3224. View

Dokla E, Fang C, Abouzid K, Chen C . 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC. Eur J Med Chem. 2019; 182:111607. DOI: 10.1016/j.ejmech.2019.111607. View

Liu J, Jin B, Su H, Qu X, Liu Y . Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report. BMC Cancer. 2019; 19(1):702. PMC: 6637526. DOI: 10.1186/s12885-019-5915-7. View

10.

Huang K, Liang Q, Zhou Y, Jiang L, Gu W, Luo M . A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer. Cell Metab. 2019; 30(6):1107-1119.e8. DOI: 10.1016/j.cmet.2019.09.014. View

11.

Jang J, To C, De Clercq D, Park E, Ponthier C, Shin B . Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations. Angew Chem Int Ed Engl. 2020; 59(34):14481-14489. PMC: 7686272. DOI: 10.1002/anie.202003500. View

12.

Liu Y, Tsai M, Wu S, Chang T, Tsai T, Gow C . Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer. Int J Cancer. 2019; 145(6):1609-1624. DOI: 10.1002/ijc.32487. View

13.

Soria J, Lee H, Lee J, Wang L, Issa J, Kemp B . Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002; 8(5):1178-84. View

14.

Ghorab M, AlSaid M, Soliman A . Dual EGFR/HER2 inhibitors and apoptosis inducers: New benzo[g]quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers. Bioorg Chem. 2018; 80:611-620. DOI: 10.1016/j.bioorg.2018.07.015. View

15.

Chau C, Steeg P, Figg W . Antibody-drug conjugates for cancer. Lancet. 2019; 394(10200):793-804. DOI: 10.1016/S0140-6736(19)31774-X. View

16.

Zhang M, Wang Y, Wang J, Liu Z, Shi J, Li M . Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Chem Pharm Bull (Tokyo). 2020; 68(10):971-980. DOI: 10.1248/cpb.c20-00411. View

17.

Gainor J, Shaw A, Sequist L, Fu X, Azzoli C, Piotrowska Z . EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016; 22(18):4585-93. PMC: 5026567. DOI: 10.1158/1078-0432.CCR-15-3101. View

18.

Scheepstra M, Hekking K, van Hijfte L, Folmer R . Bivalent Ligands for Protein Degradation in Drug Discovery. Comput Struct Biotechnol J. 2019; 17:160-176. PMC: 6369262. DOI: 10.1016/j.csbj.2019.01.006. View

19.

Cross D, Ashton S, Ghiorghiu S, Eberlein C, Nebhan C, Spitzler P . AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4(9):1046-61. PMC: 4315625. DOI: 10.1158/2159-8290.CD-14-0337. View

20.

Liu C, Huang Q, Jin Z, Zhu C, Liu Z, Wang C . miR-21 and KLF4 jointly augment epithelial‑mesenchymal transition via the Akt/ERK1/2 pathway. Int J Oncol. 2017; 50(4):1109-1115. PMC: 5363879. DOI: 10.3892/ijo.2017.3876. View